Tags: Intellectual Property
What is a trade secret? How does a trade secret differ from an intellectual property right and why choose one over the other? What measures should a company implement to best protect its trade secrets? What measures are available in the event of a breach and how can you ensure that the secret is not […]
Although the effectiveness of influencer marketing is now well-established, many brands are still confused about its legal aspects.
The Court of Justice of the European Union has given a welcome answer to the question of under what circumstances embedding, by means of the technique of framing, should be regarded as a communication to the public that requires the copyright holder’s prior authorisation.
The legal status of CBD, a naturally occurring compound found in the cannabis plant, is murky. The Court has ruled that CBD is not a narcotic drug and that the principles of free movement apply.
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine?
Reimbursement of medicinal products in times of pandemics and budgetary constraints: why quick fixes do not work
With national governments scrambling to take measures in order to counter the Covid-19 pandemic, we are again confronted with the fact that a EU common policy in the healthcare field is quasi inexistent.
In the run-up to the entry into force of specific rules on country of origin labelling for primary ingredients, the CJEU has recently clarified both the concept of the “country of origin” under the FIC Regulation and its interplay with other regulations such as the Regulation on the common organisation of the agricultural products markets and the Union Customs Code.